Toronto Dominion Bank Buys 12,984 Shares of Insulet Co. (NASDAQ:PODD)

Toronto Dominion Bank increased its position in Insulet Co. (NASDAQ:PODD - Free Report) by 55.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 36,486 shares of the medical instruments supplier's stock after buying an additional 12,984 shares during the period. Toronto Dominion Bank owned about 0.05% of Insulet worth $9,526,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in shares of Insulet in the fourth quarter worth $36,000. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Insulet by 30.1% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier's stock valued at $2,192,000 after acquiring an additional 1,942 shares during the last quarter. Jennison Associates LLC increased its holdings in Insulet by 21.8% in the 4th quarter. Jennison Associates LLC now owns 158,342 shares of the medical instruments supplier's stock valued at $41,338,000 after acquiring an additional 28,375 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in Insulet by 4.3% in the 4th quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier's stock worth $633,000 after purchasing an additional 100 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Insulet during the 4th quarter valued at about $9,822,000.

Insulet Trading Up 0.1%

PODD stock traded up $0.36 during midday trading on Monday, reaching $321.36. The company's stock had a trading volume of 693,216 shares, compared to its average volume of 708,726. Insulet Co. has a 1 year low of $171.61 and a 1 year high of $329.33. The firm has a market capitalization of $22.62 billion, a price-to-earnings ratio of 55.50, a PEG ratio of 3.62 and a beta of 1.26. The stock has a fifty day simple moving average of $271.13 and a two-hundred day simple moving average of $269.89. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business's revenue for the quarter was up 28.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.73 earnings per share. On average, equities research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on PODD. Stifel Nicolaus boosted their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Piper Sandler raised their target price on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Barclays boosted their price target on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. Finally, Citigroup reissued a "buy" rating and issued a $380.00 price objective (up from $320.00) on shares of Insulet in a research note on Thursday. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Insulet has an average rating of "Moderate Buy" and a consensus target price of $308.00.

Insider Transactions at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president now directly owns 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the company's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.